Preview: The American Society of Retina Specialists meets in Stockholm, Sweden


Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees

A view from the water of Stockholm at dawn. Image credit: ©Sergii Figurnyi –

Along with the main programme, a number of satellite symposia are planned in conjunction with the Annual Meeting. Image credit: ©Sergii Figurnyi –

The 42nd annual meeting of the American Society of Retina Specialists (ASRS) is slated to convene in the northern European capital city of Stockholm, Sweden, from July 17-20, 2024. The venue is the Stockholmsmässan Convention Center, Mässvägen 1, 125 80, Stockholm.

In addition to the extensive educational offerings available at the conference, attendees can enjoy the city’s beautiful architecture, numerous parks, and clean air, not to mention the extended daylight hours.

Those interested in attending can use the following link to register:

Conference highlights

All times listed are expressed in Central European Time.

  • The events kick off with a Foundation Event on the evening of 16 July.
  • The Opening Reception will take place on 17 July at the Grand Hotel at 7:00 pm.
  • The scientific sessions will run from 17 July to 20 July, beginning at approximately 8:30 am and lasting until 5:30 pm daily
  • The Closing Reception will be on 20 July at the Vasa Museum at 8:00 pm

Scientific sessions

Educational opportunities for attendees abound over the 4 conference days, with no aspect of retina left untouched.

The planned symposia will cover multiple sessions on most of the following topics: wet and dry age-related macular degeneration, retinal detachment, diabetic retinopathy, retinal vascular disease, hereditary retinal disease and genetics, imaging, hereditary retinal disease and genetics, therapeutic complications, inflammation and infectious disease and surgical, medical and paediatric cases.

Expert panels will be sprinkled throughout the 4 days and will address artificial intelligence, faricimab and aflibercept 8 mg in diabetic retinopathy and in wet AMD, myopic traction retinopathy, macular holes, choroidal melanoma, socioeconomics, retinopathy of prematurity, and intraocular lenses, sustainability, port delivery systems, surgical training, proliferative vitreoretinopathy, pegcetacoplan safety and a debate on surgical training after fellowship.

In addition to the in-person sessions, the virtual meeting includes mobile app access with live stream feed and access to recording with CME Credit for 1 month after the meeting, papers on demand, films and e-posters. Only the scientific symposia in the General Session Room will be live streamed and recorded. The mobile app (which includes the live stream and abstracts) will be distributed to both live and virtual attendees approximately 1 week before the event.

Satellite symposia

A number of satellite symposia are planned in conjunction with, but not in association with, the Annual Meeting. Those interested can check the ASRS meeting website for and locations and RSVP information.

17 July

7:15 - 8:15 am:A New Potential Option for Uveal Melanoma – The Science of Bel-Sar and Phase 3 CoMpass Trial. Location:Stockholmsmässan (Room: A2). RSVP to

18 July

11:45 AM - 1:00 pm: Changing the DME Game Plan with Faricimab – Dual Inhibition, Drying and Durability. Location:Stockholmsmässan (Room: A2)

6:00 – 9:30 pm (6:00 – 6:30 pm – dinner and exhibits; 6:30 – 9:30 pm – general session): Cole Eye Institute Imaging Summit Registration. Location: Radisson Blu Waterfront Hotel & Stockholm Waterfront Congress Centre, Nils Ericssons Plan 4, Box 604, 111 64
Stockholm, website:

19 July

7:00 - 8:00 am: All Eyes on Geographic Atrophy. Location:
Stockholmsmässan (Room: A4)

11:50 am - 1:05 pm: Changing the nAMD Game Plan with Faricimab - Dual Inhibition, Drying and Durability. Location: Stockholmsmässan (Room: A2)

Recent Videos
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
© 2024 MJH Life Sciences

All rights reserved.